Conversely, CLL patients with a CD38-CD49d- phenotype received great benefits when treated with targeted agents, whereas advanced age was a negative risk factor for patients treated with standard chemotherapy. The gene discussed is CD38; the disease is B-cell chronic lymphocytic leukemia.